macrophage cells. This inducible enzyme differs from the constitutive isoform found in endothelial as well as other cell types and is now believed to be responsible for the sustained vasodilatation and hypotension that characterize septic shock (4) . Indeed. the hypotension induced by T N F can be completely reversed after administration of NG-monomethyl-L-arginine (L-NMMA). an L-arginine analogue that inhibits N O synthase (5) . The aim of our present study was to investigate whether N O is increased in neonatal rats suffering from fatal infection and, if so, whether anti-TNF MAb would interfere with N O production and whether circulating N02-/N03-levels would correlate with the protective efficacy of these antibodies.
MATERIALS AND METHODS
/Inir?~als. Ten-d-old newborn Wistar rats (18 to 24 g) were used. All rats were born at our facility and remained with their dam until the loth day of life. O n d 10, the rats were removed from the dams and fasted for 4 h in a controlled temperature environment without access to water.
Orgat1ism.
A gentamicin-susceptible strain of P. acnrgino.sa from a clinical isolate (belonging to Fisher-Devlin-Gnabasik immunotype IV) was used to infect the animals. The organisms were stored in 10% glycerin at -70°C until ready for use. The day before challenge, the isolate was streaked on trypticase soy agar and incubated overnight at 37°C. The next day, the bacteria were suspended in sterile normal saline and adjusted spectrophotometrically to a predetermined inoculum size of 10" organisms/ mL.
In our laboratory, an inoculum of lo9 live P. aer~rgit~osa/g body weight was a 90% lethal dose within 24 h in 10-d-old rats when gentamicin was initiated (5 mg/kg, twice a day) 2 h after the bacterial challenge. This dose of P. arrlrginosa and gentamicin was used in all subsequent experiments, and the bacteria were injected s.c. into the dorsum after the skin was washed with 75% alcohol.
Anti-TNF hflih prcparatiotz. The murine-derived anti-recombinant human T N F MAb (designated Z8), which has been shown to have similar neutralization of recombinant human T N F and rat TNF, was prepared and provided by the Institute of Military Medical Sciences of PLA (Beijing. China). The IgGl anti-TNF MAb was free of endotoxin (<0.05 &mg of protein) as determined by the Limulus lysate gelation assay.
E.\pcrinrmtal Design. P. aer~cginosa challenge. Thirty-five newborn rats were individually injected with the bacteria as well as gentamicin, as mentioned above. Then, at the designed time point ( 0 , 2 , 4 , 6 , 8, 10, and 12 h postinjection), five newborn rats were killed and the central blood samples were collected in heparinized tubes. Blood samples were immediately centrifuged, SHI E and plasma samples were stored at -70°C until assay for TNF, glucose, and lactic acid, except the blood samples for assay of N02-/NO3-, which were protein-precipitated (30% ZnS04, 0.05 mL/mL of blood) before centrifugation. Blood cultures were also performed aseptically.
Anti-TNF AlAb orland de.~amc~tl~asone cotreatmcnt. Ten-dold rats were divided into four groups (n = 22) and received intraperitoneal injections in addition to the bacteria and gentamicin mentioned above as follows: group 1, 0.1 mL of saline; group 2, 0.1 mL of anti-TNF MAb (28, 5 mg/kg); group 3, 0. l mL of dexamethasone (5 mg/kg); and group 4, 0.1 mL of anti-TNF MAb (28, 5 mg/kg) in combination with dexamethasone (5 mg/kg). At 6 and 12 h postinjection, five newborn rats in each group were killed, and the central blood was collected for assay. The other 12 neonatal rats in each group served as observed subjects for the count of 24-h mortality. Necropsy cultures were obtained from the newborn rats who died and from those surviving animals killed at 24 h, the end of the experiment.
Assays. Assay ofN02-/NO3-levels. N02-/NO3-level has been confirmed to be a good indicator for NO production (6). The method described by Hegesh and Shiloah (7) was used with slight modifications. One mL of plasma sample was passed through a cadmium reduction column (100 X 8 mm) pre-washed with distilled water, 0.1 mol/L HCI, distilled water, and ammonium hydroxide buffer (0.1 mol/L, pH 9.6), 5 mL of each. Passing through the column, nitrate is quantitatively reduced to nitrite. After application of the sample, the column was eluted with a 3.42 mol/L NaCl solution in 0.05 mol/L, pH 9.6, ammonium chloride buffer. One 5.0-mL fraction of the emuent was collected immediately after the application, and to it, 0.5 mL of a 29.0 mmol/L sulfanilamide solution in 6.4 mol/L HCI was added. The tube was mixed, and 3 min later 0.2 mL of 19.3 mmol/L N-(I-naphthy1)ethylenediamine dihydrochloride was added. Absorbance of the pink color was measured after 20 min at 540 nm. More than 90% ofthe nitrite was found in the 5-mL fraction. Dilutions of sodium nitrite were used to prepare a standard curve. We did not attempt to differentiate between NOz-and NO3-amounts, inasmuch as very little N02-was found in the circulation (7) .
Detection of TNF levels. The bioassay for TNF using the L 929 cell line has been described elsewhere (8) . In our laboratory, 1 U corresponded to 1.67 pg recombinant murine TNF (Genzyme Corporation, Cambridge, MA).
Assay for glticose and lactic acid concentrations. Blood samples were processed for glucose and lactic acid by routine methods (9) .
Statistical analysis. The x2 test or t test, Wilcoxon two-sample test, and, when more than two groups were involved, KruskalWallis test, and the Spearman rank-correlation coefficient were used. All data were presented as mean + SD, unless specified otherwise. Significance was accepted at p < 0.05.
RESULTS
P. aerlrginosa challenge. Blood cultures performed at 0, 2, and 4 h postchallenge revealed none positive for P. aenrginosa. However, blood cultures obtained at 6, 8, and 10 h revealed documented bacteremia in 40% of the killed animals, and the incidence of the bacteremia reached 80% at 12 h. Figure 1 depicts the time course of plasma N02-/NO3-changes in the challenge test. The fatal infection in newborn rats caused a gradual rise of plasma N02-/N03-to rather high levels. The plasma NO2-/NO3-levels were significantly elevated by 6 h and peaked at 12 h postchallenge.
The time course of changes in plasma TNF levels of the septic newborn rats is summarized in Figure 2 . The plasma TNF levels rose rapidly to a peak at 6 h and then gradually declined to very low levels.
The 90% lethal dose of P. aerlcginosa challenge in the newborn rats induced metabolic derangements, that is, the changes of circulating levels of glucose and lactic acid. The basal levels of lactic acid were 1.56 f 0.34 mmol/L at 0 h, and hyperlacticemia developed continuously with markedly elevated levels at 8 h (2.88 f 0.27 mmol/L; p < 0.05) and the peak levels at 12 h (6.01 f 0.54 mmol/L; p < 0.05 compared with those at 0 and 8 h). Anti-TNF A111 6 orland desar)~ethasone cotreatmcnt. There were no significant differences ( p > 0.05) among the incidence of positive blood cultures for P. aertiginosa in the four experimental groups (40% in control or dexamethasone group, 20% in anti-TNF MAb or combined-cotreatment group at 6 h; 60% in all four groups at 12 h). Necropsy of the animals that died during the experimental course all revealed documented bacteremia, whereas necropsy of the surviving rats killed at the end of the experiment revealed bacteremia in 67% of the anti-TNF MAb group, 83% of the dexamethasone group, and 55% of the combined cotreatment group. The only animal that survived in the control group was bacteremic when killed at 24 h.
Cotreatment with anti-TNF MAb or dexamethasone was found to not only decrease the plasma TNF levels but also attenuate the plasma No2-/NO3-levels statistically. Moreover, when anti-TNF MAb was used in combination with dexamethasone, the suppression of TNF and N02-/NO3-concentrations in the circulation was even more remarkable compared with that when using anti-TNF MAb or dexamethasone alone (Table 1) .
The metabolic derangements of the septic newborn rats were markedly improved after administration of anti-TNF or MAb orland dexamethasone. As shown in Table 2 , anti-TNF MAb remarkedly decreased mortality in the neonatal rat model of P. acrtiginosu infection, and dexamethasone had a similar effect. Furthermore, the two combined produced additional benefits.
DISCUSSION
Our present study demonstrated that NO production was significantly increased in neonatal rats with fatal infection caused by P. aerziginosa. Circulating NOz-/NO3-, appearing slightly later than TNF, was statistically detectable by 6 h and peaked 12 h postchallenge. In adult animal models, endotoxin and toxic shock syndrome toxin 1 have been shown to increase NO production (6, 10). Ochoa ct a/. (1 1) first reported elevated plasma levels of N02-/NO3-in human adults suffering from sepsis. Moreover, in a very recent study, we found highly elevated circulating nitrogen oxide during the course of human neonatal sepsis and its association with the occurrence of septic shock (unpublished observations).
TNF has been described to enhance NO production in vitro (4). In our study, in newborn rats that received anti-TNF MAb injections, not only plasma TNF levels but also plasma NO2-/ Nos-concentrations were statistically attenuated. We suggest that TNF secretion, preceding NO production, might be associated with NO release in vivo.
In the present study, we discovered that anti-TNF MAb therapy altered the time course of hypoglycemia and hyperlacticemia and finally decreased the mortality in 10-d-old septic rats. The protective efficacy of anti-TNF MAb may correlate with the suppression of NO production, and also with the modulation in metabolic abnormalities. We suggest that the suppression of NO production might be at least partly responsible for the effects of anti-TNF MAb that protect newborn rats from septic death, because overproduction of NO has been confirmed to lead to profound vasodilation, hypotension, inadequate tissue perfusion, and metabolic dyshomeostasis (3).
Corticosteroids have been reported to prevent the induction of inducible NO synthase without affecting the activity of constitutive enzyme. Prior treatment with dexamethasone could attenuate NO-mediated cytotoxicity in immunologically stimulated endothelial cells and the hypotension produced by endotoxin in vivo (12, 13) . Our present data showed that dexamethasone had an inhibitory effect on NO production similar to that ofanti-TNF MAb; this suppressive action might contribute partly to its protection of the animals from septic death. Moreover, we confirmed, for the first time, that the use of anti-TNF MAb plus dexamethasone further decreased circulating TNF and NO2-/ N03-levels, improved hypoglycemia and hyperlacticemia, and finally increased the survival rates in the septic newborn rats even compared with the efficacy using either anti-TNF MAb or dexamethasone alone. Considering that corticosteroids have been shown only to inhibit inducible NO synthase but not to suppress the constitutive isoform that has a role in the physiologic control of blood pressure, the therapy by anti-TNF MAb in combination with dexamethasone may have practical value (14) .
To summarize, our present study indicated that NO production would be increased in the model of P. aerlrginosa infection in neonatal rats, and the highly elevated circulating N02-/NO,-level, a good indicator for NO production, could be decreased by anti-TNF MAb therapy with and without steroids. Thus, we suggested that the protective efficacy of anti-TNF MAb may correlate with the suppression of NO production and also with a modulation in metabolic abnormalities in the septic newborn animals.
